New England Journal of Medicine· 2022Q1

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Scott D. Solomon, John J.V. McMurray, Brian Claggett, Rudolf A. de Boer et al.

2,697citations
Q1SCImago
2022year

Short summary

Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death by 18% (HR 0.82) in patients with heart failure and preserved or mildly reduced ejection fraction (LVEF >40%) over a median of 2.3 years.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine